BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy

Catia Mio, Lorenzo Gerratana, Marco Bolis, Federica Caponnetto, Andrea Zanello, Mattia Barbina, Carla Di Loreto, Enrico Garattini, Giuseppe Damante, Fabio Puglisi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation. Aims of our study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clinical strategies through the combinations of the pharmacological induction of epigenetic BRCAness in BRCA1 wild-type triple negative breast cancer (TNBC) cells by means of BET inhibitors and compounds already available in clinic. Performing a dual approach (chromatin immunoprecipitation and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells. Moreover, BRD4 pharmacological inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent reduction in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells. Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281). Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells. Noteworthy, being this strategy based on drugs already available for human use, it is rapidly transferable and could potentially enable clinicians to exploit platinum salts and PARP inhibitors-based treatments in a wider population of TNBC patients and not just in a specific subgroup, after validating clinical trials.

Original languageEnglish
Pages (from-to)755-766
Number of pages12
JournalInternational Journal of Cancer
Volume144
Issue number4
DOIs
Publication statusPublished - Feb 15 2019

Fingerprint

Triple Negative Breast Neoplasms
Recombinational DNA Repair
DNA Damage
Neoplasms
Proteins
Homologous Recombination
Platinum
Therapeutics
Salts
Pharmacology
Phenotype
Chromatin Immunoprecipitation
RNA Interference
Epigenomics
DNA Repair
Cell Death
Clinical Trials
Gene Expression
Pharmaceutical Preparations
Population

Keywords

  • BET inhibitors
  • BRCAness
  • homologous recombination
  • synthetic lethality
  • triple negative breast neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

BET proteins regulate homologous recombination-mediated DNA repair : BRCAness and implications for cancer therapy. / Mio, Catia; Gerratana, Lorenzo; Bolis, Marco; Caponnetto, Federica; Zanello, Andrea; Barbina, Mattia; Di Loreto, Carla; Garattini, Enrico; Damante, Giuseppe; Puglisi, Fabio.

In: International Journal of Cancer, Vol. 144, No. 4, 15.02.2019, p. 755-766.

Research output: Contribution to journalArticle

Mio, C, Gerratana, L, Bolis, M, Caponnetto, F, Zanello, A, Barbina, M, Di Loreto, C, Garattini, E, Damante, G & Puglisi, F 2019, 'BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy', International Journal of Cancer, vol. 144, no. 4, pp. 755-766. https://doi.org/10.1002/ijc.31898
Mio, Catia ; Gerratana, Lorenzo ; Bolis, Marco ; Caponnetto, Federica ; Zanello, Andrea ; Barbina, Mattia ; Di Loreto, Carla ; Garattini, Enrico ; Damante, Giuseppe ; Puglisi, Fabio. / BET proteins regulate homologous recombination-mediated DNA repair : BRCAness and implications for cancer therapy. In: International Journal of Cancer. 2019 ; Vol. 144, No. 4. pp. 755-766.
@article{20f4d84d0e6b468b91ccd43fa100a0bb,
title = "BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy",
abstract = "Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation. Aims of our study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clinical strategies through the combinations of the pharmacological induction of epigenetic BRCAness in BRCA1 wild-type triple negative breast cancer (TNBC) cells by means of BET inhibitors and compounds already available in clinic. Performing a dual approach (chromatin immunoprecipitation and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells. Moreover, BRD4 pharmacological inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent reduction in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells. Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281). Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells. Noteworthy, being this strategy based on drugs already available for human use, it is rapidly transferable and could potentially enable clinicians to exploit platinum salts and PARP inhibitors-based treatments in a wider population of TNBC patients and not just in a specific subgroup, after validating clinical trials.",
keywords = "BET inhibitors, BRCAness, homologous recombination, synthetic lethality, triple negative breast neoplasms",
author = "Catia Mio and Lorenzo Gerratana and Marco Bolis and Federica Caponnetto and Andrea Zanello and Mattia Barbina and {Di Loreto}, Carla and Enrico Garattini and Giuseppe Damante and Fabio Puglisi",
year = "2019",
month = "2",
day = "15",
doi = "10.1002/ijc.31898",
language = "English",
volume = "144",
pages = "755--766",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - BET proteins regulate homologous recombination-mediated DNA repair

T2 - BRCAness and implications for cancer therapy

AU - Mio, Catia

AU - Gerratana, Lorenzo

AU - Bolis, Marco

AU - Caponnetto, Federica

AU - Zanello, Andrea

AU - Barbina, Mattia

AU - Di Loreto, Carla

AU - Garattini, Enrico

AU - Damante, Giuseppe

AU - Puglisi, Fabio

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation. Aims of our study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clinical strategies through the combinations of the pharmacological induction of epigenetic BRCAness in BRCA1 wild-type triple negative breast cancer (TNBC) cells by means of BET inhibitors and compounds already available in clinic. Performing a dual approach (chromatin immunoprecipitation and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells. Moreover, BRD4 pharmacological inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent reduction in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells. Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281). Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells. Noteworthy, being this strategy based on drugs already available for human use, it is rapidly transferable and could potentially enable clinicians to exploit platinum salts and PARP inhibitors-based treatments in a wider population of TNBC patients and not just in a specific subgroup, after validating clinical trials.

AB - Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation. Aims of our study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clinical strategies through the combinations of the pharmacological induction of epigenetic BRCAness in BRCA1 wild-type triple negative breast cancer (TNBC) cells by means of BET inhibitors and compounds already available in clinic. Performing a dual approach (chromatin immunoprecipitation and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells. Moreover, BRD4 pharmacological inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent reduction in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells. Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281). Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells. Noteworthy, being this strategy based on drugs already available for human use, it is rapidly transferable and could potentially enable clinicians to exploit platinum salts and PARP inhibitors-based treatments in a wider population of TNBC patients and not just in a specific subgroup, after validating clinical trials.

KW - BET inhibitors

KW - BRCAness

KW - homologous recombination

KW - synthetic lethality

KW - triple negative breast neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85058061500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058061500&partnerID=8YFLogxK

U2 - 10.1002/ijc.31898

DO - 10.1002/ijc.31898

M3 - Article

C2 - 30259975

AN - SCOPUS:85058061500

VL - 144

SP - 755

EP - 766

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -